Enanta Pharmaceuticals
ENTA
181 hedge funds and large institutions have $1.19B invested in Enanta Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 59 increasing their positions, 51 reducing their positions, and 16 closing their positions.
251% more call options, than puts
Call options by funds: $4.22M | Put options by funds: $1.21M
219% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 16
45% more capital invested
Capital invested by funds: $824M → $1.19B (+$369M)
22% more funds holding
Funds holding: 148 → 181 (+33)
16% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 51
3.57% more ownership
Funds ownership: 73.38% → 76.95% (+3.6%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$38M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$15.1M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$9.58M |
| 4 |
Bank of New York Mellon
New York
|
+$5.79M |
| 5 |
Renaissance Technologies
New York
|
+$5.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$16.3M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$12.8M |
| 3 |
Millennium Management
New York
|
-$10M |
| 4 |
KAM
Krensavage Asset Management
New York
|
-$9.78M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$5.65M |
ENTA Hedge Fund Activity: Q1 2018 in Review
181 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2018, worth a combined $1.19B — up 45% from $824M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new ENTA positions and 16 closed out — a net gain of 35 holders — while 59 added to existing stakes and 51 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $38M. The largest seller was First Manhattan, cutting an estimated $16.3M.
- 181 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2018, up from 148 in Q4 2017.
- Funds reported $1.19B of Enanta Pharmaceuticals stock for Q1 2018, up 45% quarter-over-quarter.
- 51 funds opened new Enanta Pharmaceuticals positions in Q1 2018 and 16 closed out, a net change of +35 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2018 was Janus Henderson Group, an estimated $38M added.
- The largest Enanta Pharmaceuticals seller in Q1 2018 was First Manhattan, an estimated $16.3M sold.
Based on aggregated 13F filings for Q1 2018.